Digital Bridge to Faster Trials:
Where Expertise Meets Efficiency
Accessing Subject Matter Experts (SMEs) pathologists for clinical trials is often challenging. Their in-depth expertise and extensive experience significantly contribute to trial accuracy and quality.
The lack of streamlined, interoperable pathology data systems across clinical trial locations hinders efficient digital review and sharing, complicating the management of diverse data sources.
Pharmaceutical companies have straightforward needs, but meeting them consistently is a challenge. Samples need to be returned to trial sites as fast as possible to ensure trial progression and prevent patient drop-out.
Pathologist input plays a critical role in ensuring the overall success of clinical trials. Today, patients have more detailed visit and procedure schedules across complex trials. Easing patient burden and wait time increases retention levels.
Diagnexia technologies are designed to address these challenges and prevent delays in pathology sample reviews.
We enable faster pathologist review turnaround times. This engages investigators and allows clinical trial sites to progress efficiently whilst retaining valuable patients.
The unified Diagnexia platform offers immediate pathology image data sharing, fostering collaboration among pathologists, investigators, sponsors, and other stakeholders.
Diagnexia's platform accommodates multiple formats and file types, allowing for digital scanning of glass slide samples (WSI) and seamless ingestion of pathology images. High-quality images are readily available for swift review by study pathologists.
Diagnexia offers a range of services to support clinical trials and ensure data quality and compliance.
Diagnexia's services listed below cover various core disease areas, including:
Digitally enable your Key Opinion Leaders (KOLs) with tools for enhanced trial involvement
On-call global expert pathologists ensuring continuous trial oversight
Anytime, anywhere access to crucial digital pathology data
Precision Medicine development: Biomarkers and identification of patients most likely to benefit
Enhanced patient-centricity through accessible digital patient profiles
Adaptable digital platform scaling with your trial’s needs
Quality control and quality assurance processes to ensure reliability of digital data
Secure and Compliant Data Management
Seamless digital collaborations among global trial stakeholders
Digitisation services for historic clinical program content and glass samples
The team was curated with individuals recognised as sub-speciality experts. Many have earned international acclaim, stand as key opinion leaders in their domains, and are exceptionally experienced pathologists equipped to handle the vast scope of expertise needed in clinical trials.
Dr. Tom Hu is currently serving as an Assistant Professor of Clinical Pathology & Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania, a role he has held since April 2022.
Dr. Hu completed his Doctor of Medicine (M.D.) at Wayne State University in 2016, and he has undergone postgraduate training in various facets of pathology. His academic journey and contributions reflect his dedication to the field of pathology and specifically Breast Pathology & Cytopathology.
Dr. Hu’s professional interests encompass a wide array of topics, including cytopathology, breast pathology, and bone and soft tissue pathology. He is involved in academic and clinical teaching, with a focus on educating the next generation of medical professionals.
Dr. Hu has participated in research projects and quality improvement initiatives, including the molecular pathology quality improvement project. His contributions demonstrate a commitment to advancing the field and improving patient care.
Dr. Hu is an active member of several professional and scientific societies, including the International Society of Breast Pathology and the American Society of Cytopathology. He has also served as a Junior Ad Hoc Member of the Case Study Committee for the American Society of Cytopathology, indicating his involvement in shaping the standards and practices of the field.
Dr. Hu’s research has been published in reputable journals. Notable publications include papers on ovarian carcinoma progression and the diagnostic value of ancillary studies in serous effusion cytology. These publications demonstrate his contributions to the scientific community.
Dr. Hu has taken on editorial roles as an ad Dr. Hu has taken on editorial roles as an ad hoc reviewer for Diagnostic Cytopathology and Archives of Pathology & Laboratory Medicine, contributing to the peer review process for esteemed journals and ensuring the dissemination of high-quality research
His professional interests are diverse and include teaching, resident education, and various areas of pathology, such as cytopathology, breast pathology, bone and soft tissue pathology.
Dr. Tom Hu’s dedication to education, research, and quality improvement in the field of pathology makes him a valuable asset to the medical community and a promising figure in the realm of clinical pathology and laboratory medicine.
Dr. Anita Bane is an accomplished Anatomic Pathologist based at Toronto General Hospital, University Health Network. With a strong academic affiliation, she has accumulated extensive experience in her field and made significant contributions to global breast cancer research and treatment. Dr. Bane’s journey through academia, research, and clinical work has been impressive. She holds a Ph.D. in Molecular Biology & Cancer Genetics from the University of Toronto, emphasising her strong research-focused background.
Dr. Bane’s academic journey started with her MB, BAO, BCh degree from University College Hospital Galway, Galway, Ireland, showcasing her early commitment to the field. Over the years, she continued to pursue higher education and received her Ph.D. in Molecular Biology & Cancer Genetics from the University of Toronto in 2007.
She gained practical experience through Clinical Fellowships and Residency positions, including Clinical Fellowship in Surgical Pathology at Mount Sinai Hospital, University of Toronto, and Residency in Anatomic Pathology and Cytopathology at Trinity College, Dublin, Ireland. Dr. Bane holds prestigious certifications, such as FRCPath from the Royal College of Pathologists, United Kingdom, and MRCPI from the Royal College of Physicians, Ireland, demonstrating her commitment to professional growth and development.
With close to two decades of experience, she has served as an Adjunct Associate Professor in Oncology at McMaster University and has held various roles, including Staff Pathologist, Chief of Pathology, and Medical Director of Laboratory Medicine at Cambridge Memorial Hospital.
Throughout her career, Dr. Bane has received numerous awards and honours, including the Donald W. Penner Award from the Canadian Association of Pathologists and the Ontario Institute for Cancer Research (OICR) Clinician-Scientist Award.
Her extensive involvement in professional organisations such as the United States and Canadian Academy of Pathology and the Royal College of Physicians & Surgeons of Ontario underscores her dedication to the field of pathology. Notably, she has actively contributed to grant and manuscript reviews, indicating her role in shaping research standards and advancements in her field.
Dr. Bane’s research interests primarily revolve around breast cancer, focusing on understanding the genotype-phenotype correlation and developing biomarkers for improved treatment. Her dedication to breast pathology is evident in her involvement in various breast pathology workshops and her notable publications in peer-reviewed journals. Her research has been pivotal in advancing the understanding and management of breast cancer.
Professor of Pathology at the University of California, San Francisco (UCSF) Director of the UCSF Gastrointestinal Pathology Service, Chief of the UCSF Gastrointestinal Pathology Consultation Service.
With Over 30 years in the field of pathology, with a focus on gastrointestinal pathology.
Gastrointestinal pathology, Hepatic pathology, Molecular alterations in colorectal cancer, Barrett’s esophagus and esophageal adenocarcinoma.
Involved in numerous clinical trials, particularly those related to colorectal cancer and other gastrointestinal malignancies.
Played a pivotal role in establishing international standards in gastrointestinal pathology. Involved in the development of guidelines for the management of patients with hereditary gastrointestinal cancer syndromes.
“WHO Classification of Tumours of the Digestive System” (4th Edition)
“AJCC Cancer Staging Manual” (8th Edition)
“WHO Classification of Tumours of the Digestive System” (5th Edition)
Numerous research articles and book chapters related to gastrointestinal and hepatic pathology.
Editor-in-Chief, “American Journal of Surgical Pathology” (AJSP), Editorial board member of several other pathology journals, including “Modern Pathology” and “Histopathology”.
Dr. Clara Limbaeck currently holds the role of Consultant Neuropathologist at the Department of Neuropathology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust.
Dr. Clara Limbaeck has had a significant academic association with the esteemed Imperial College, London. In addition to serving as an Honorary Senior Lecturer at the Division of Brain Sciences, she has been a dedicated lecturer to both medical and graduate students in Neurosciences at the Faculty of Medicine. This connection underscores her commitment to education and her involvement in shaping the next generation of professionals in her field.
From the time she obtained her Medical Degree in 1994, Dr. Limbaeck’s notable career in neuropathology has spanned several decades, establishing her as an expert with extensive experience working in Italy, Slovenia, USA & UK.
Dr. Limbaeck’s research interests are deeply rooted in neuropathology. She has shown a particular inclination towards primary CNS tumours, molecular pathology, and inflammatory myopathies. She teaches and trains in neuropathology for trainees in the Histopathology and Neuropathology, Department of Neuropathology, Oxford University Hospitals NHS Foundation Trust.
Her commitment to neuropathology is further demonstrated through her publications. Dr. Limbaeck has been the lead author in significant works, including “Cerebrospinal fluid cytology findings in a case of diffuse leptomeningeal glioneuronal tumour”, “2021 classification of tumors of the central nervous system: a review for the neuroradiologist”, and “Characterization of IDH mutant WHO grade 2 and 3 gliomas: magnetic resonance imaging predictors of 1p/19q codeletion and tumor grade.”
Dr. Limbaeck has actively contributed to the scholarly community as a Co-editor for the renowned “Frontiers in Neurology” journal.
Dr. Craig Peter Charles Dick is a Consultant Histopathologist with expertise in Thoracic Pathology, currently serving at the Department of Pathology in Queen Elizabeth University Hospital, Glasgow. He holds a prominent position as an Honorary Senior Lecturer at the University of Glasgow, reinforcing his commitment to education and research. A Subject Matter Expert in Lung Cancer Clinical Trials, Lung Imaging and Pathological Correlation and Mesothelioma.
Dr. Craig Dick’s academic affiliation with the University of Glasgow highlights his dedication to advancing the field of pathology through education and research.
With extensive experience in pathology, Dr. Dick’s PhD journey across breast carcinoma research, led him to become a Consultant Histopathologist, specialising in Thoracic Pathology. His career trajectory includes research fellowships and a strong foundation in both clinical practice and academic pursuits. Dr Dick has worked extensively in researching lung cancers and mesothelioma.
Dr. Dick’s research interests cover a broad spectrum of topics in the field of pathology, with a focus on thoracic pathology.
His contributions have ranged from publications on mesothelioma to studies on EGFR mutation demographics, offering valuable insights into lung cancer and pleural malignancies.
Dr. Dick has made valuable contributions to the field of pathology through his publications. Some key publications include studies on mesothelioma, lung cancer demographics, and biomarkers of pleural malignancy, which have advanced the understanding of these conditions.
Dr. Craig P.C. Dick’s career is marked by a commitment to education, research, and clinical practice in the field of pathology. His contributions through publications and academic roles underscore his significant impact on the understanding and treatment of thoracic pathology and related conditions.
Dr. Dani S. Zander is a distinguished physician with an extensive career in Anatomic and Clinical Pathology, specializing in Lung Pathology and Cytopathology.
Dr. Dani Zander is currently serving as the MacKenzie Professor and Chair of the Department of Pathology and Laboratory Medicine at the University of Cincinnati (UC) College of Medicine. She also holds the position of Chief of Pathology and Laboratory Medicine at UC Health. Her academic affiliation is with the University of Cincinnati College of Medicine, where she contributes as a faculty member in the Pathobiology and Molecular Medicine PhD Program. Throughout her career, she has held various academic positions, starting as an Assistant Professor at the University of Florida and later becoming a Professor at the University of Texas Health Science Center at Houston Medical School.
Dr. Zander boasts over 35 years of experience in the field of pathology.
Dr. Zander’s research interests are primarily centered on inflammatory and neoplastic lung diseases. Her expertise in lung pathology has positioned her as a leading expert in the field.
Dr. Zander has actively participated in 11 clinical trials, aiding in the advancement of diagnostic and therapeutic strategies for various diseases across her career.
Dr. Zander has played a key role in establishing international standards in pathology. She is affiliated with numerous professional organizations and serves on various committees, such as her fellowship with the College of American Pathologists and her involvement with the American Society of Clinical Pathology.
Dr. Zander has an impressive publication record with 82 refereed publications in esteemed scientific and medical journals.
She has authored 19 book chapters and served as an editor or co-editor for four published books.
Dr. Zander has taken on significant editorial roles, having edited or co-edited four published books and is in the process of working on another.
Dr. Bryson holds affiliations as an Honorary Clinical Associate Professor at the University of Glasgow and an Honorary Senior Lecturer at the University of St Andrews.
Dr. Bryson has substantial experience, notably serving as the Head of Service for Pathology from 2016-2020 and currently as Clinical Director for Laboratory Medicine at the Queen Elizabeth University Hospital, Glasgow.
His interests encompass efficient systems, laboratory modernisation, and digital pathology, with a focus on workload measurement within the pathology domain. Rotating through six pathology departments during his training, he gained extensive exposure to a full range of complex specimens including expert supervision in areas of soft tissue, hematolymphoid and renal pathology.
Expert reviewer for PROTECTOR Clinical Trial (risk reducing surgery for patients at risk of tubo-ovarian high grade serous carcinoma), also ad hoc support for a variety of trials (selecting blocks and reviewing slides etc).
Glasgow MRC Molecular Pathology Board - served on the Project Board of this group, representing NHS GGC pathology.
Leading iCAIRD (Industrial Centre for Artificial Intelligence in Digital Diagnostics), a large-scale project with a primary objective of fully digitising the pathology department of NHSGGC to be the largest digital pathology service in Europe.
Dr. Bryson is involved in several committees and working groups, such as the Royal College of Pathology Digital Pathology Committee and the National Labs Programme Digital Pathology Sub-committee, indicating an active role in shaping pathology standards, particularly in digital pathology.
Dr. Gareth Bryson has made significant contributions to the field of pathology and oncology research. His contributions span a range of topics including the guidance for remote reporting of digital pathology slides, especially during challenging service pressures, as demonstrated in a paper from the UK Royal College of Pathologists. He has also been involved in the genetic investigation of ovarian carcinoma, identifying unique mutational processes and copy number signatures. Additionally, Bryson’s work has explored the clinical and pathological aspects of cervical carcinomas, oral and oropharyngeal carcinomas, and the potential carcinogenic properties of hernia repair prostheses.
Prof. Gregory Lauwers is affiliated with the H. Lee Moffitt Cancer Center and Research Institute as a Senior Member and Director of GI pathology. Additionally, he serves as a Professor of Cell Biology & Pathology and Oncologic Sciences at the University of South Florida, Tampa.
Dr. Lauwers began his professional journey in 1986 and has amassed decades of experience in the field of pathology. His tenure includes prestigious appointments at institutions like Harvard Medical School, University of Florida, and Massachusetts General Hospital.
Dr. Lauwers' research predominantly focuses on gastrointestinal pathologies, with an emphasis on gastric and esophageal adenocarcinomas, their molecular markers, and associated conditions. Additionally, he has a keen interest in tumour biology, immunohistochemistry, and the development and evaluation of treatments, including surgical and pharmacological interventions for gastrointestinal diseases.
Professor Lauwers has worked in clinical trials acting as Consultant Pathologist, Consultant, Co-Investigator and Study Investigator for Top 10 Pharma Sponsors, CROs, Labs and Med Dev companies, working across GI and associated trials
Prof. Lauwers has made significant contributions to the field of pathology, as evident by his contributions to the WHO Classification of Tumours of the Digestive System, both in the 4th and 5th editions (2010 and 2019).
Dr. Lauwers has made significant contributions to the understanding of gastrointestinal diseases, with pivotal publications addressing the cellular and molecular markers in gastric and esophageal adenocarcinomas. His work delves into the intricacies of tumor biology, providing insights into the roles of proteins like bcl-2 and p53 in the progression of these cancers. Additionally, through collaborative studies, Lauwers has evaluated surgical and pharmacological treatments, highlighting their impact and outcomes in the management of gastrointestinal conditions.He has also contributed to multiple editions of the WHO Classification of Tumours of the Digestive System.
Dr. Lauwers has been an Ad hoc Reviewer for numerous renowned journals such as Cancer, International Journal of Cancer, Gastroenterology, and Modern Pathology. He has also taken on various editorial roles such as Coordinating Editor for the University of Florida GI Cancer Letter, Deputy Editor in Chief for the Archives of Pathology and Laboratory Medicine, and several editorial board roles in prestigious journals like the American Journal of Clinical Pathology, Archives of Pathology and Laboratory Medicine, and American Journal of Surgical Pathology.
Dr. Jan Lukas Robertus is an esteemed Consultant Cardiothoracic and Transplant Pathologist at the Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust in London, UK. He also holds positions as a Visiting Professor at the University of Antwerp, Belgium and an Honorary Senior Clinical Lecturer in the National Heart and Lung Institute, Imperial College London.
With an impressive medical journey beginning in 2001 from the University of Utrecht, The Netherlands, Dr. Robertus has amassed over two decades of experience in the medical and research fields.
His research interests prominently feature Thoracic oncology and computational pathology, which he pursued during his research appointment from 2015-2020 at the Royal Brompton and Harefield Hospitals.
Dr. Jan Lukas Robertus has contributed significantly to the field of medical research, particularly in relation to medical imaging, pathology, and cardiovascular topics.
Notably, Robertus has been involved in studies examining malignant mesothelioma with the use of artificial intelligence, the imaging of human organs down to the cellular scale, and various research on heart-related topics, including the diagnosis and management of arrhythmias, primary tumors of aorta and pulmonary arteries, and the recellularization of cell-free allogenic heart valves. In addition, his contributions also span areas like the grading system in epithelioid malignant pleural mesothelioma and the oncogenic MYC-miR-150- MYB network in Burkitt lymphoma.
Dr. Robertus has been actively involved in various editorial boards and committees. He is a Member of the Editorial Board for the Pathology Portal, where he leads for AI. He also offers his expertise as a Scientific Advisory Board Member of the German Covid Registry and a Board member of the AI center Data Access Committee at The London Medical Imaging and AI Center for Value-Based Healthcare, to name a few.
Dr.John Gross currently serves as an Assistant Professor of Pathology and Orthopaedic Surgery at Johns Hopkins University School of Medicine, Baltimore, MD. His affiliation with Johns Hopkins started in 2020 and has expanded across multiple departments, underlining his multidisciplinary expertise.
Dr Gross’ clinical focus is the diagnosis of bone and soft tissue tumours and general surgical pathology. He has a special interest in molecular oncology and how molecular abnormalities can be detected for diagnostic and therapeutic purposes, reviewing >3,600 patient cases each year.
Dr Gross provides Bone and Soft Tissue consultation practice in which cases are sent for diagnostic opinion from pathologists in Europe, China, Israel, Panama, Iceland, Canada, Lebanon, Bahamas, various African countries, as well as nearly every state in the continental United States of America.
Having acquired his MD degree in 2012, Dr. Gross has approximately 11 years of rich professional experience in the medical field, complemented by his multiple residencies and fellowships in esteemed institutions like the Cleveland Clinic Florida, Creighton University, University of Washington, and Mayo Clinic.
Dr. Gross’s key research interests emerge from his vast publications. His work delves into various aspects of pathology, with an emphasis on soft tissue, bone, and surgical pathology. Some specific topics include USP6 gene rearrangements, paraspinal pseudoneoplasms, chondroblastoma, and the impact of UV-mutation signatures in sarcomas.
Dr. Gross’s extensive research contributions, especially in pathology, highlight his potential involvement in shaping understandings and possibly standards in the field including improving turnaround times and Quality Improvement in Decalcification of Bone Specimens.
Dr. Gross has an impressive portfolio of publications. Among his original research are papers on cellular fibroma of tendon sheath and chondroblastoma in adults. He’s authored review articles such as one emphasising the Biphenotypic Sinonasal Sarcoma’s differential diagnosis. Moreover, his case reports span a range from penile cancer cases influenced by HPV to granular cell tumours. Apart from journal publications, he has co-authored various book chapters that encompass topics like spinal chordoma and multiple facets of lung pathology.
Dr. Kai Duan is an accomplished and highly regarded medical professional with a distinguished career in the field of Pathology. His extensive academic background and years of experience have established him as a leading expert in the domain. Dr. Duan currently serves as an Assistant Professor in the Faculty of Medicine at the University of Toronto, specializing in the Department of Laboratory Medicine and Pathobiology.
He has a rich educational history, having earned his MD, CM (Doctor of Medicine and Master of Surgery) degree from the Faculty of Medicine at McGill University in Quebec, Canada. Dr. Duan further honed his skills through rigorous postdoctoral and specialty training, including a Clinical Fellowship in Liver and Gastrointestinal Pathology at the University Health Network and the University of Toronto.
With a passion for advancing medical knowledge and improving patient outcomes, Dr. Duan is an active participant in clinical trials and research. Notably, he served as a Study Pathologist for the Ontario-wide Targeted Nucleic Acid Evaluation (OCTANE) project conducted by the Ontario Institute for Cancer Research.
Dr. Duan has been instrumental in contributing to the establishment of international standards in pathology, and he holds several esteemed positions. He is a Fellow of the College of American Pathologists (FCAP), a Diplomate of the American Board of Pathology (DABP), and a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC). He is licensed to practice independently by the College of Physicians and Surgeons of Ontario.
His noteworthy publications in reputable scientific journals showcase his dedication to research and include articles on topics such as pancreatic cancer, adrenal cortical carcinoma, and neuroblastoma. Furthermore, Dr. Duan’s commitment to the field is evident through his involvement in the editorial boards of various prestigious publications.
Dr. Kai Duan’s contributions to the field of Pathology, encompassing his academic affiliations, extensive experience, involvement in clinical trials, and pivotal role in setting international standards, have solidified his reputation as a distinguished figure in the world of medicine. His influential publications and editorial roles highlight his dedication to advancing the practice of pathology and its impact on patient care.
Dr. Kossivi Dantey is Staff Pathologist and Cytopathologist, Director of Cytopathology at Allegheny Health Network and Assistant Professor, Drexel University College of Medicine. His academic journey is marked by several distinguished affiliations. He completed a Cytopathology Fellowship at the University of Pittsburgh Medical Center between 2016 and 2017. In 2016 also Bone & Soft Tissue Pathology visiting Fellowship with Dr. CDM Fletcher, MD atBrigham and Women’s Hospital; Harvard Medical School, Boston, MA. Prior to that, he undertook a Bone and Soft Tissue Pathology Fellowship at University of Pittsburgh Medical Center from 2015 to 2016. He also pursued an AP/CP Residency at the University of Vermont Medical Center in Burlington, Vermont, in 2015. Dr. Dantey’s academic aptitude is further emphasised by his bilingual prowess, being fluent in both English and French.
Over the span of more than 18 years, Dr. Dantey has accumulated vast professional experience. He began his illustrious career as a Quality Control Analyst in 2005 and has since scaled significant heights. Currently, he holds a pivotal role as a Staff Pathologist and Cytopathologist at Allegheny General Hospital, a position he has embraced since 2017.
Dr. Kossivi Dantey’s research interests primarily encompass the detailed study of tumours, particularly myxoid solitary fibrous tumours and their histopathological characteristics. He has also delved into the realms of hepatobiliary and pancreatic diseases, as well as the nuances of diagnostic techniques in surgical pathology. Furthermore, his work includes significant contributions to the understanding of lung lesions, vascular neoplasms of the spleen, and the implications of immunosuppressive therapy on tumour formation.
Dr. Dantey’s contributions to medical literature are both profound and varied. He has been credited with numerous peer-reviewed publications, exploring topics such as solitary fibrous tumours, subsolid lung lesions, hepatobiliary and pancreatic conditions, vascular neoplasms of the spleen, and more. Additionally, he has co-authored chapters in esteemed books, with a notable mention being a chapter in “Differential Diagnosis in Surgical Pathology, 4th edition.”
Beyond his research and clinical responsibilities, Dr. Dantey has consistently contributed to the academic community as a peer reviewer for the Journal of Clinical Pathology since 2013, thereby upholding the rigorous standards of the pathology domain.
Dr. El-Bahrawy holds a dual position as a Professor of Practice of Histopathology at the Department of Histopathology, Imperial College London, United Kingdom (since September 2019) and as a Professor of Pathology at Alexandria Faculty of Medicine, Egypt (since February 2018).
Her illustrious career started with her role as a house officer at Alexandria University Hospitals in 1990, and since then she has held numerous prominent academic and clinical positions in both Egypt and the United Kingdom, including serving as an Associate Professor at Alexandria Faculty of Medicine and an Adjunct Reader at Imperial College London.
With a professional journey spanning over three decades, Dr. El-Bahrawy brings to the table over 30 years of experience in histopathology and academic research.
Dr. El-Bahrawy has dedicated her career to understanding the molecular mechanisms and clinical presentations of gynaecological malignancies, particularly ovarian cancer. Her investigations encompass areas like the potential roles of Claudin-3 and Claudin-4 in ovarian cancer management and the molecular pathology of gynaecological malignancies. At Imperial, she oversees PhD student projects, participating in under- and postgraduate teaching, lecturing and conducting practical sessions. Dr El-Bahrawy is actively involved in research & innovation and treatment groups across renowned medical institutions, thought leader groups across cancer, biobanks, ovarian cancer and translational research
Dr. El-Bahrawy has been actively involved in groundbreaking research surrounding the clinical management of ovarian cysts.Her experience spans 13 studies for large Pharma, from Phase I/Ib through Phase III in cancer patients / ovarian cancer / solid tumour patients. Her notable contribution is the “Study Protocol for a Randomised Controlled Trial on the use of Intraoperative Ultrasound Guided Laparoscopic Ovarian Cystectomy (UGLOC) as a method of fertility preservation in the management of benign ovarian cysts.”
Dr. Mona El-Bahrawy has made significant contributions to the field of gynaecological malignancies and their molecular and clinical underpinnings. Her work has delved into potential management roles of specific proteins like Claudin-3 and Claudin-4 in ovarian cancer, as well as utilising intraoperative ultrasound in fertility preservation during the treatment of benign ovarian cysts. Furthermore, she has extensively explored various biomarkers, gene fusions, and molecular mechanisms associated with ovarian tumours, endometriosis-associated ovarian carcinomas, and other related conditions, offering insights into diagnosis, prognosis, and treatment strategies.
Dr. Monika Hofer serves as a Consultant Neuropathologist at Oxford University Hospitals NHS Foundation Trust and holds the prestigious position of Honorary Senior Clinical Lecturer at The University of Oxford. This dual role underscores her commitment to both clinical practice and academic excellence.
Dr. Hofer has accumulated extensive experience through her impressive academic journey and a distinguished career in the field of diagnostic neuropathology. Dr. Monika Hofer’s significant role as a Consultant Neuropathologist and Honorary Senior Clinical Lecturer at Oxford University Hospitals NHS Foundation Trust and The University of Oxford showcases her dedication to both patient care and academic progress. Her research interests in Neuromuscular Pathology and CNS Tumors demonstrate her commitment to advancing diagnostic methods and knowledge in complex neurological domains. Her key publications contribute to the evolving landscape of neuropathology, benefiting patients and fellow researchers alike.
Dr. Hofer’s research focuses on Neuromuscular Pathology and CNS Tumors, which are vital areas in the realm of diagnostic neuropathology, contributing to advancements in understanding and diagnosing neurological disorders.
“Utilising clinical parameters to improve the selection of nerve biopsy candidates” (2023); “Autophagy in non–immune-mediated rhabdomyolysis: Assessment of p62 immunohistochemistry” (2023), “Modern Solutions for Ancient Pathogens: Direct Pathogen Sequencing for Diagnosis of Lepromatous Leprosy and Cerebral Coenurosis” (2022); “Acute small-fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination: A report of three cases and review of the literature” (2022); “Mitochondrial dysfunction in anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune-mediated necrotising myopathy” (2022);
These recent publications collectively underscore Dr. Monika Hofer’s significant contributions to the field of neuropathology and its progression currently into more patient focused treatments, enriching the diagnostic and clinical landscape of neurological disorders and strengthening her position as an expert in this complex domain.
Dr. Vyas is a renowned expert in Gastrointestinal and Liver pathology.
Dr. Monika Vyas’s significant academic association is with the renowned Beth Israel Deaconess Medical Center. Her time there underscores her commitment to both research and clinical practice, making her a distinguished figure in the institution.excellence.
Dr. Vyas’s vast expertise in the realm of pathology is evidenced by her work both in India and the United States over her career. The diversity of her experiences across different healthcare systems has only deepened her understanding of various clinical challenges.
Her research endeavours focus on leveraging histological insights to boost diagnostic precision, prognostic capabilities, and therapeutic strategies. Some of her standout achievements include discerning unique molecular markers in intraductal pancreatic neoplasms, shedding light on NTRK fusions in paediatric thyroid malignancies, and demystifying the complex genetic underpinnings of mismatch repair deficient gastrointestinal and gynecologic tumours.
Actively immersing herself in clinical trials including research on the ramifications of chemotherapy on the proliferation metrics of neuroendocrine carcinomas made its way into the esteemed American Journal of Surgical Pathology.
Beyond her research and clinical pursuits, Dr. Vyas is resolutely dedicated to sculpting international benchmarks in pathology. This commitment showcases her forward-thinking approach and positions her as a pioneering figure in her domain.
With over 25 peer-reviewed outputs, inclusive of articles, reviews, and book sections, Dr. Vyas’s scholarly footprint is profound. Her presence is also palpable at national pathology conventions, like USCAP and CAP. Further, her contributions to “pathologyoutlines.com” ensure that her insights reach a global audience of professionals in her field.
Dr. Vyas’s regular presentations at major pathology symposiums, along with her contributions to online platforms, underscore her dedication to disseminating knowledge.
Dr. Nicole Cipriani is an accomplished pathologist with a wealth of experience in the field.
Associate Professor at the University of Chicago in the Department of Pathology, Division of Anatomic Pathology. With over a decade of academic appointments and a Diplomate of the American Board of Pathology in Anatomic and Clinical Pathology, Dr. Cipriani has established herself as a respected figure in her area of expertise.
With a clinical practice dating back to 2013, Dr. Cipriani brings over a decade of extensive experience to her role as an Associate Professor and Medical Director of Gross Pathology and AP Informatics. Her wealth of knowledge and expertise has greatly benefited her institution and the broader medical community.
Her research interests cover a wide spectrum of topics within pathology, including thyroid and salivary gland pathologies, as demonstrated by her extensive body of work. Dr. Cipriani has a substantial record of peer-reviewed publications in leading medical journals, showcasing her dedication to advancing the understanding of various diseases. Some of her noteworthy key publications include studies on NUTM1-rearranged carcinoma of the thyroid, secretory carcinoma of the salivary gland, and practical immunohistochemistry in the classification of salivary gland neoplasms.
Dr. Cipriani’s involvement in research extends to case reports, where she explores unique clinical cases and presents her findings. Notable examples include her work on vocal cord paralysis caused by histoplasmosis and the presence of actinomycosis in the larynx and pharynx.
Dr. Cipriani has actively engaged in clinical trials, harnessing her expertise to contribute to the development of novel diagnostic and treatment strategies for various pathologies, including studies treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer; A Phase II Trial of multiple brand name Induction Chemotherapy medicines Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer; MSD’s study in patients taking brand name Humanized antibodies with Chemotherapy.
Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer; MSD’s study in patients taking Pembrolizumab with Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors.
Dr. Cipriani is recognized for her vital role in shaping and establishing international standards in the field of pathology.
Her dedication to maintaining the highest quality and consistency in pathology practice is commendable.
Dr. Cipriani has an impressive list of key publications that have significantly influenced the field of Surgical Pathology.
Professor Berney is an internationally-Pedro Oliveira, MD is a distinguished Consultant in Histopathology, recognized for his extensive experience and significant contributions to the fields of anatomic pathology, urological pathology and dermatopathology.
Dr. de Oliveira is currently affiliated with The Christie Hospital NHS Foundation Trust, where he has served as a Consultant in Histopathology since April 2016.
With over 27 years of experience in the field of Histopathology, Dr. Oliveira’s expertise is widely recognized.
He has been actively involved in academic endeavours, including lecturing medical students at the University of Manchester and serving as an assistant lecturer in Pathology at Nova Medical School, Lisbon, Portugal. Dr. Pedro de Oliveira’s dedication to advancing the field of Histopathology, coupled with his extensive research and clinical experience, positions him as a leading expert in uropathology and a valuable contributor to international standards in pathology. His commitment to both academia and clinical practice further highlights his significant impact on the medical community. He is a leader for the Uropathology area, reviewing some 600 cases in-house and 2500 external reviews & second-opinion cases year. He is a MDTs leader for Testis North-West, Penile Cancer and Greater Manchester centre for Radical prostatectomies, unknown tumours, thyroid neoplasms, and Lung cancer, with responsibility for the ALK/ROS1/PD-L1 assessment at Christie Hospital.
His research interests span a range of uropathology-related areas, including hypoxia resistance in prostate cancer, genomic markers, inflammation, and macrophage activity in prostate cancer, radiomics in prostate cancer, and genomic biomarkers in Cancer of Unknown Primary, among others.
Dr. de Oliveira has actively contributed to clinical trials, notably the “PEACE Study” led by Cancer Research UK and UCL Cancer Trials Centre and others with The Christie Hospital.
Contributions extend to being a leader in the “RCPath new Penile Cancer Dataset” and a member of the “EAU Guidelines in Penile Cancer.
Recent publications include works on hereditary leiomyomatosis and renal cell cancer, frozen section examination in testicular tumours, and investigations into radiotherapy response in prostate cancer.
Dr. de Oliveira’s expertise has been acknowledged through his role as President of the College of Portuguese Pathologists, along with other professional memberships in pathologist organizations.
Dr. Ranmith Perera is currently a Consultant Pathologist at the Department of Cellular Pathology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. He also holds a position as a Visiting Professor in Pathology at St Georges University, Grenada, West Indies.
Dr. Perera has accumulated extensive experience in pathology since earning his MD from St. Georges University, Grenada, West Indies. His career has spanned various roles, including Specialist Registrar in Histopathology, Research Fellow in Renal Medicine, and Consultant Pathologist, across multiple institutions in the UK and Sri Lanka since at least 1995.
Dr. Perera has a keen interest in renal medicine, particularly in areas related to transplant pathology. His work involves microscopy reporting medical renal (native and transplant), pancreas (transplant), and cardiovascular biopsies, among other responsibilities.
Dr. Perera is a member of several pathology-related societies, including the Pathological Society of Great Britain and Ireland, The Association of Clinical Pathologists, International Academy of Pathology (British division), and the Ceylon College of Pathology, which suggests an active role in the pathology community.
Clinical-pathological Correlations in Post-Transplant Thrombotic Microangiopathy (Histopathology 2019). Oxford Classification of IgA nephropathy 2016—the role of crescentic lesions: an update from the IgA Nephropathy Classification Working Group (Kidney International 2016). Incidence and Outcome of C4d Staining with Tubulointerstitial Inflammation in Blood Group incompatible Kidney Transplantation (Transplantation, 2015 Jul; 99(7): 1487-94)
Robert Najarian is an accomplished specialist in Anatomic Pathology with a primary focus on Gastrointestinal, Liver, and Pancreatobiliary Pathology. Dr. Najarian brings extensive experience and expertise to his field, and he has made notable contributions in various areas of medicine.
Previously affiliated with Harvard Medical School, where he completed a prestigious Fellowship in Gastrointestinal and Liver Pathology at Beth Israel Deaconess Medical Center.
Dr. Najarian has gained significant experience in the field of Gastrointestinal and Liver Pathology, with a focus on gastrointestinal diseases, liver disorders, and pancreatic pathologies.
Dr. Najarian has a profound interest in a range of gastrointestinal and hepatobiliary conditions, including Barrett’s esophagus, esophagitis, gastric cancer, celiac disease, inflammatory bowel disease, colorectal cancer, pancreatic cancer, liver neoplasia, and non-alcoholic fatty liver disease/steatohepatitis.
His clinical expertise extends to various studies and clinical trials, contributing significantly to the advancement of treatment for gastrointestinal and hepatobiliary conditions.
Dr. Najarian has authored numerous publications that have enriched the medical literature. His works cover topics ranging from metabolic syndrome and diabetes to gastrointestinal disorders, celiac disease, and pancreatic pathologies.
Dr. Robert Najarian’s significant contributions to the field of Anatomic Pathology, particularly in Gastrointestinal and Liver Pathology, underscore his expertise and dedication to advancing our understanding of complex gastrointestinal and hepatobiliary diseases. His extensive experience, academic background, and research interests make him a valuable figure in the medical community.
Dr. Sanjay Logani has held various prestigious academic positions over the years. From 2009 to 2016, he served as a Clinical Instructor at the Department of Pathology, University of WA. Since 2016, he has been an Assistant Professor at the same institution. Additionally, from 2015 onward, Dr. Logani has been an Associate Professor at the Department of Pathology, Elson S. Floyd College of Medicine, WSU in Spokane, WA.
With his academic journey beginning with an MBBS in 1992 from Maulana Azad Medical College, Dr. Logani brings over 30 years of experience to the table, enriching the field with his profound expertise.
Dr. Sanjay Logani’s main research interests encompass the morphological and molecular characterization of tumours, particularly in the fields of cytology, histopathology, and gynecologic oncology.
Dr. Logani’s contributions are noteworthy in this regard. In 2006, he was a member of the Standards of Practice Task Force of the Papanicolaou Society of Cytopathology, affiliated with the United States and Canadian Academy of Pathology. Furthermore, in 2007, he was involved with the Committee on Utilisation of Ancillary Techniques in Thyroid Cytology at NIH, Bethesda, MD.
Dr. Sanjay Logani has made significant contributions to the medical field with his extensive research articles.
His publications touch upon various subjects, from distinct morphological studies such as the characterization of “Clear cell cholangiocarcinoma of the liver” to deep dives into intricate topics like the “Molecular characterization of uterine clear cell carcinoma”. Moreover, his research has provided vital insights into the fields of cytology and histopathology, as evidenced by his work on the immunoprofile of ovarian tumours, the significance of p53 in endometrial neoplasia, and the diagnostic criteria for fine needle aspiration of hepatocellular carcinoma, among many others.
Dr. Logani’s editorial endeavours are commendable. Between 2007 and 2009, he co-edited the Monograph series on Gynecologic Cytology for Cytojournal. He has also generously contributed as a manuscript reviewer for esteemed journals, including the Archives of Pathology and Laboratory Medicine, Cytojournal, Diagnostic Cytopathology, Cytopathology, and Cancer Cytopathology.
Dr. Steven Tahan, a renowned figure in the realm of Dermatopathology, has cultivated a distinguished career marked by academic affiliation, extensive years of experience, pioneering research interests, involvement in clinical trials, contributions to international pathology standards, notable publications, and active editorial board roles.
Dr. Steven Tahan has held a prominent position at the Department of Pathology, Beth Israel Deaconess Medical Center, located at 330 Brookline Ave, Boston, MA 02215. Here, he has demonstrated exceptional clinical expertise and innovation, making significant contributions to the field of Dermatopathology.
Paul van Diest’s work has earned him With over four decades of dedicated service in the field of pathology, Dr. Tahan brings a wealth of experience and a profound understanding of dermatopathology.
Dr. Tahan has shown a diverse range of research interests, from pioneering innovative diagnostic techniques to shedding light on the pathogenesis of various dermatological conditions. His contributions to medical knowledge are reflected in his innovative research endeavours.
Dr. Tahan has been actively involved in clinical trials, collaborating with major pharmaceutical and medical institutions across his tenures at Harvard, Yale, Tufts University School of Medicine and Massachusetts General. His role as a reference pathologist in significant drug trials including participating as pathologist on safety committee for serious cutaneous adverse reactions to new drugs (Phase II and Phase III). Participated as main reference pathologist for development of melanoma gene signature assay. Participated as pathologist assessing treatment efficacy of novel therapy for lichen sclerosus. In a professional consultative capacity working with Institutions conducting studies, Diagnostics & Medical Device companies and pharmaceutical companies.
Dr. Tahan has made significant contributions to the establishment of international standards in pathology. His expertise is sought by national clinical diagnostic laboratories and legal entities, underlining his role in shaping clinical practice and diagnostic standards.
Dr. Tahan has made significant contributions to the field through a substantial body of publications. His works, spanning diverse aspects of dermatopathology, have become crucial references for scholars and clinicians alike.
As an influential figure in the field, Dr. Tahan has served on the editorial boards of esteemed journals, ensuring the dissemination of high-quality research and playing a vital role in knowledge dissemination.
Dr. van der Kwast’s academic journey started with his medical studies at Erasmus University Rotterdam, where he completed his Ph.D. thesis on “Cellular and genetic requirements for delayed type hypersensitivity.” His impressive career includes various academic appointments, such as Associate Professor and later Professor in Pathology at Erasmus University Rotterdam.
In 2004, he joined the Department of Pathology and Laboratory Medicine at Mount Sinai Hospital in Toronto, Canada, as Staff Pathologist and Section Head of Surgical Pathology. He continues to contribute significantly to the field at the University Health Network. His distinguished career includes multiple awards and honours, including the Leopold Koss medal of the International Society of Urological Pathology for his life-time achievements in Uropathology (2017). He has over 500 peer-reviewed publications and a H-score of 125.
Dr. Theo H. van der Kwast’s research interests focus on early detection of prostate cancer, biomarker development for prostate cancer and molecular diagnostics of urothelial cancer. His work includes projects related to personalized cancer diagnosis, prognosis, and drug development.
Dr. van der Kwast has been involved in clinical trials related to cancer, particularly in the genitourinary area including Bladder and Prostate Cancer trials to determine eligibility and randomization / patient outcomes. (Phase II/III)
He has actively participated in international committees and conferences related to pathology, where he has contributed to the standardization of diagnostic and reporting criteria, especially in prostate and bladder cancer pathology.
Dr. Theo H. van der Kwast has significant peer review publications dating from 1974 to the present including:’Androgen receptors in endocrine therapy-resistant
human prostate cancer’. Int. J. Cancer 48, 189-193, 1991; ‘Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry.’ Am. J. Pathol. 161, 329-332, 1994; ‘Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy’: EORTC 22911. J ClinOncol 2007
Dr. Theo H. van der Kwast has contributed to various editorial boards, ensuring the quality and accuracy of research publications in the field of pathology.
Dr. van Diest is a distinguished cancer researcher whose career has been dedicated to advancing our understanding of cancer and improving diagnostic and treatment strategies. With a wealth of experience and a strong research background, he has made significant contributions to the field of pathology and oncology.
Paul van Diest’s academic journey began with his studies in Medicine, which led him to pursue his PhD and pathology residency at the VU University Medical Center (VUMC) in Amsterdam. He achieved Board certification in Pathology in 1996, and from there, he took on the role of Consultant Pathologist at the Department of Pathology at VUMC. He steadily progressed through the academic ranks, becoming an Associate Professor in 1999 and a full Professor in 2001. In 2003, he moved to Utrecht to lead the Department of Pathology at the University Medical Center Utrecht (UMCU), where he continues to make significant contributions.
Paul van Diest’s work has earned him recognition not only in the Netherlands but also on the international stage. He holds the position of Adjunct Professor of Oncology at the Sidney Kimmel Oncology Center at Johns Hopkins in Baltimore, USA. This underscores his global impact and collaborative efforts in the field of cancer research.
His commitment to advancing the field is further exemplified by his active role on the editorial boards of more than 20 international journals. As a peer reviewer, he plays a crucial role in ensuring the dissemination of high-quality research and scientific knowledge.
Paul van Diest’s extensive research portfolio includes over 700 papers published in peer-reviewed journals. His work has covered a wide array of topics in pathology and oncology, with a primary focus on finding ways to prevent, diagnose, and treat breast cancer, addressing both male and female forms of the disease. His dedication to improving cancer care and outcomes is evident through his numerous grants, including those from prominent institutions like the NIH and the Dutch Cancer Society.
Dr. Victor Prieto, MD, PhD, is an esteemed figure in the field of pathology, specialising in Dermatopathology, Cancer and Soft Tissue Pathology. With an extensive academic background and a wealth of experience, he has left an indelible mark on the field through his contributions to research, clinical trials, and the establishment of international pathology standards.
Dr. Victor Prieto currently serves as the Professor and Chair of the Department of Pathology at the University of Texas – MD Anderson Cancer Center. His role also extends to the Department of Dermatology at the same institution, where he holds the position of Professor. Through his academic affiliations, he has played a pivotal role in shaping the education and training of future pathologists and dermatologists.
Since 1990, Dr.r Prieto has worked in dermatopathology in Spain and the USA, Dr. Prieto brings a wealth of knowledge and expertise to the field. His extensive experience has been instrumental in advancing patient care and medical knowledge.
Dr. Prieto’s research interests encompass a broad spectrum, including neoplasms, melanoma, sentinel lymph nodes, and neoadjuvant therapy. His contributions to these areas have led to significant advancements in the understanding and treatment of dermatological conditions.
Dr. Prieto has actively participated in clinical trials, collaborating with leading institutions and pharmaceutical companies. His involvement as a consultant spans skin science technologies and genetic testing and health screening trials, underscoring his commitment to advancing patient care and treatment through innovative research.
Dr. Prieto’s expertise is not confined to academic and clinical settings. His influence extends to the establishment of international standards in pathology. His contributions to the field have been recognized on a global scale, making him a key figure in shaping best practices and standards.
Dr. Prieto’s significant contributions are reflected in his key publications, which have become essential references for scholars and clinicians alike. His work spans critical aspects of dermatopathology, furthering our understanding of various skin condition and diseases.
As a respected authority in the field, Dr. Prieto has served on editorial boards of prestigious journals. His role in evaluating and disseminating research has been instrumental in advancing the field of pathology and dermatopathology.
Dr. Fisher is an Emeritus Professor of Tumour Pathology at the Institute of Cancer Research, University of London, UK. He previously held the position of Professor of Tumour Pathology at the same institute and served as Consultant Histopathologist at various institutions, including the Royal Marsden NHS FT, London, UK.
Dr. Fisher has had an extensive career spanning over four decades in pathology. Currently Consultant Histopathologist, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK reviewing some 3,000 cases each year and also a national and international second opinion service for soft tissue tumours based at Royal Orthopaedic and subsequently University Hospitals, Birmingham UK.
His interests include morphology, immunohistochemistry, molecular pathology, and clinico-pathological correlations.
Dr. Fisher has been a Co PI and lead / reference pathologist for numerous national and international panels, including Prostate Cancer Trials PR06 and RT01 and EORTC Soft Tissue and Bone Group Pathology Panel; Clinical relevance of glypican co-receptors in rhabdomyosarcomas and other tumours’ and ‘Translational research in individuals with genetic predisposition to cancer’.
Dr. Fisher participated in the Consensus Group for the World Health Organization Classification of Tumours of Soft Tissue and Bone. He was also a member of UICC Expert Panel for Review of TNM System and served in various capacities in national and international pathology panels and schemes.
Dr. Fisher has been credited with over 650 peer-reviewed papers and three textbooks. “Biopsy Interpretation of Soft Tissue Tumors” and “Atlas of Soft Tissue Tumor Pathology” are among his significant works.
Throughout his career, Dr. Fisher has been involved with numerous professional bodies, committees, and societies, playing pivotal roles in many. He served as Past-President of the International Society of Bone and Soft Tissue Pathology and the Royal Society of Medicine’s Oncology Section. Dr. Fisher’s memberships span associations like the Arthur Purdy Stout Society of Surgical Pathologists, Society for Ultrastructural Pathology, American Society of Clinical Pathologists, and more.
Professor Berney is an internationally-recognized Genito-urinary and Endocrine pathologist.
Professor Daniel Maurice Berney holds a distinguished academic position as the NHS professor of Genito-Urinary Pathology at Barts Cancer Institute, affiliated with the esteemed Queen Mary University of London.
With a career that spans over two decades, Professor Berney is Consultant Histopathologist, Barts and The London NHS Trust & NHS professor of Genito-Urinary Pathology, Barts Cancer Institute, Lead at Barts Health NHS Trust for GU and Endocrine tumours.
Professor Berney’s commitment to research is evident in his impressive repertoire of over 270 peer-reviewed journal publications. His in-depth research explorations have garnered him an outstanding H score of 68. His investigations primarily revolve around genito-urinary pathology, contributing to deeper insights and advancements in the field.
Professor Berney has been significantly involved in various clinical trials including Metastatic renal cancer, Phase II predictive & prognostic markers in RCC; PIII Investigation of HER targeted therapy in metastatic bladder cancer; ZEBRA study, NEPTUNE study for Top 10 Pharma companies
A testament to his influence is his instrumental role in formulating international standards for pathology classifications. His leadership and insights have been crucial in setting the benchmarks and best practices in pathology.
With an extensive list of over 270 peer-reviewed publications, Professor Berney’s influence in academic literature is profound. His contributions also span several book chapters, further solidifying his position as an authority in his field.
Professor Berney’s editorial prowess is evident in his role as the Editor in Chief of “Histopathology.” Additionally, he has lent his expertise to the editorial boards of several other influential medical journals. His perspective is highly sought-after, as seen in his role as an expert advisor for the national prostate research collaborative, PROMPT.
Supplementing these achievements, Professor Berney’s active participation in national and international medical organizations, such as ISUP, IAP, and the Royal College of Pathologists, further showcases his commitment to the global medical community. His leadership in the British Association of Uro-Pathologists (BAUP) and his pivotal role as its chairman underlines his influential stature in uro-pathology in the UK.
Prof. Runjan Chetty is a distinguished figure in the field of medicine, renowned for his expertise in pathology and healthcare leadership. His journey in the medical world began at the Royal College of Surgeons in Ireland, where he received numerous accolades, including the prestigious Arthur Jacobs Open Scholarship. Prof. Chetty boasts an impressive array of qualifications, including MB BCh BaO, FFPath, and FRCPA.
Throughout his illustrious career, Prof. Chetty has held pivotal positions at esteemed institutions such as Brighton and Sussex University Hospitals and the University of Toronto. His contributions have extended beyond clinical practice, as he has actively participated in various working groups and societies, focusing on advancing our understanding and treatment of diseases, including colorectal carcinoma and pancreatic cancer.
Prof. Chetty has also held the Chairs of Pathology at the University of Natal, Durban, South Africa, and the University of Glasgow (St Mungo Norman Chair of Pathology).
Prof. Chetty’s expertise is not limited to practice and research alone. He has played a significant role in shaping the direction of medical knowledge as a distinguished member of several editorial boards, including Pathology, Endocrine Pathology, Modern Pathology (2011-2019), Human Pathology, and many others. His insightful contributions have influenced the content and quality of publications in renowned journals, further solidifying his reputation as a thought leader in the field of medicine.
In addition to his remarkable career and editorial contributions, Prof. Chetty has made significant contributions to the medical field through his extensive body of publications. As of August 14, 2023, his work has garnered a remarkable 16,800 citations, showcasing the profound impact of his research. He has written on a diverse range of topics ranging from infections to the morphological and molecular aspects of disease as well as the diagnostic utility of digital pathology workflows and AI. He has 485 peer reviewed publications.
Currently, Prof. Chetty holds the esteemed position of Chief Medical Officer and Senior Consultant Pathologist at Deciphex Ltd, where he continues to showcase his commitment to healthcare innovation and leadership. With his unwavering dedication to pathology, education, and research, Prof. Runjan Chetty remains a revered figure in the global medical community, leaving an indelible mark on the field. His multifaceted contributions to medicine make him a respected leader and scholar in the healthcare landscape.
Dr. Vikram Deshpande, an accomplished anatomical pathologist, specialising in gastrointestinal tract, liver, and pancreas diseases. His professional journey has been closely tied to the Massachusetts General Hospital and Harvard Medical School, where he is affiliated as faculty and contributes to clinical care in Gastrointestinal and Bone and Soft Tissue Pathology.
Massachusetts General Hospital and Harvard Medical School
He has been actively involved in academic Over 13 years
Dr. Deshpande’s pioneering work focuses on IgG4-related disease (IgG4-RD), which evolved from obscurity to recognition as a well-characterized systemic disease. His studies in the early 2000s were instrumental in establishing IgG4-RD as a multi-systemic disease with protean clinical manifestations. He has made substantial contributions to understanding and diagnosing this condition, helping to distinguish it from mimics and guiding treatment strategies.
Dr. Deshpande played a pivotal role in reporting the effectiveness of an anti-CD20 antibody in treating IgG4-RD. his contributions have refined the diagnosis of pancreatic and hepatic neoplasms. These neoplasms include pancreatic ductal adenocarcinoma, pancreatic endocrine tumours, acinar cell cystadenoma, acinar cell carcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
He led an international group of clinicians and pathologists to develop guidelines for the histologic diagnosis of IgG4-RD, setting the standard for diagnosing this fibroinflammatory disease.
Dr. Deshpande’s extensive list of publications includes seminal work on IgG4-RD, pancreatitis, and various neoplasms, contributing significantly to the understanding of these diseases.
Dr. Deshpande has served on editorial boards, notably as an editor of a textbook on bone pathology, now in its second edition.
Dr. Deshpande is dedicated to education.
He has played a substantial role in educating pathologists, physicians, and surgeons about IgG4-RD through reviews, textbook chapters, and lectures. He has also been actively involved in teaching and supervising medical students, earning recognition as a top teacher by the Division of Anatomic Pathology.
Dr. Deshpande provides administrative oversight to the MGH tumour repository, facilitating research and patient safety. He also oversees the MGH Biodiscovery Laboratory, supporting clinical and scientific investigations.
This critical sector is under pressure. Digitisation might be its saviour.
The Toronto Diagnexia Accessioning Office is Now Open
Join our esteemed Chief Medical Officer, Prof. Runjan Chetty, in another insightful installment of our "Challenging Cases" webinar series, this time delving into the nuanced realm of Gynecologic Pathology.
Join our Chief Medical Officer, Prof. Runjan Chetty, as he hosts the next webinar in our "Challenging Cases" series, focusing this time on the intricate world of Prostate Pathology.
Our podcast series touches on topics like the future of pathology, innovation and digital pathology. The impact of this on practice, use of diagnostic algorithms & challenges confronting pathology across the world in the next 5-10 years.
In this episode, we're joined by Andrea Gooding, Specialty General Manager for Cellular Pathology at Nottingham University Hospitals, and our very own Anthony Johnson, UK Sales Manager
In the second episode of our series Diagnexia Dialogues we speak to Bob McGonnagle and Moira Larsen